A Phase 3 interventional study of Metformin and LY2189265 in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 91 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 7 that started in 2010, is one of 22 in phase 3, and was the 7th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 807 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 35th largest by enrollment of the 232 interventional ones that give a count, is one of 16 that started in 2010, is one of 85 in phase 3, and was the 47th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if LY2189265 is safe and effective in reducing glycosylated hemoglobin (HbA1c) as compared to metformin in participants with Type 2 Diabetes.
The term rescue therapy in this trial was defined primarily as additional nontrial antidiabetic medication for the management of severe, persistent hyperglycemia or alternative antidiabetic medication following study drug discontinuation. For efficacy analyses, participants who received rescue medication were included in the analysis population, but only measurements obtained prior to taking rescue therapy were included in the efficacy analysis. For safety analyses, with the exception of hypoglycemia outcomes, all measurements including those obtained after taking rescue therapy were included in the analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52
Drug: LY2189265 · Drug: Placebo (oral)
LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52
Drug: LY2189265 · Drug: Placebo (oral)
Metformin: 500 milligrams per day (mg/day), orally, for Week 1; 1000 mg/day, orally, for Week 2; 1500 mg/day, orally, for Week 3; 2000 or at least 1500 mg/day, orally, for Weeks 4 through Week 52 Placebo: subcutaneously (SC), once weekly for 52 weeks
Drug: Metformin · Drug: Placebo (subcutaneous)
Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \[OAM\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \[OAM\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.
Time frame: Baseline, 52 weeks
Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of Less Than 7% and Less Than or Equal to 6.5% at 26 and 52 Weeks
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, prior medication group, and treatment as factors included in the model.
Time frame: 26 weeks and 52 weeks
Change From Baseline to 26 and 52 Weeks in Fasting Blood Glucose
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles
The SMBG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (daily mean) were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline daily mean as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Body Weight
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline body weight as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Body Mass Index (BMI)
Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline BMI as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Homeostasis Model Assessment of Beta-cell Function
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline HOMA2 as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL) Score
The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP) Score
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Status Version
The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.
Time frame: Baseline, 26 weeks, and 52 weeks
Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Change Version
The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) score is used to assess relative change in participant satisfaction from baseline. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 (much less satisfied) to +18 (much more satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.
Time frame: 52 weeks
Change From Baseline to 26 and 52 Weeks in the Diabetes Symptoms Checklist Participant-reported Outcome (DSC-r) Score
The Diabetes Symptoms Checklist-revised (DSC-r) was designed to assess the presence and perceived burden of diabetes-related symptoms. Respondents were to consider troublesomeness of 34 symptoms on a 5-point scale ranging from 5="extremely" to 1="not at all." For symptoms/side-effects not experienced, the item was scored as 0. Symptoms were grouped into the following subscales: psychology-fatigue, psychology-cognitive, neurology-pain, neurology-sensory, cardiology, ophthalmology, hypoglycemia, and hyperglycemia. Subscale scores were calculated as the sum of the given subscale divided by the total number of items in the scale. Total score was computed from the sum of the 8 subscales and ranged from 0 to 40. Higher scores indicate greater symptom burden. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.
Time frame: Baseline, 26 weeks, and 52 weeks
Number of Participants With Treatment Emergent Adverse Events at 26 and 52 Weeks
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: 26 weeks and 52 weeks
Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate
Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects and baseline interval as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Pulse Rate
Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Blood Pressure
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks, and 52 weeks
Percent Change From Baseline to 26 and 52 Weeks in Total Cholesterol
Percent changes in total cholesterol were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.
Time frame: Baseline, 26 weeks, and 52 weeks
Percentage Change From Baseline to 26 and 52 Weeks in High Density Lipoprotein Cholesterol (HDL-C)
Percentage changes in HDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.
Time frame: Baseline, 26 weeks, and 52 weeks
Percentage Change From Baseline to 26 and 52 Weeks in Low Density Lipoprotein Cholesterol (LDL-C)
Percentage changes in LDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.
Time frame: Baseline, 26 weeks, and 52 weeks
Percentage Change From Baseline to 26 and 52 Weeks in Triglycerides
Percentage changes in triglycerides were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes
Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Serum Calcitonin
Time frame: Baseline, 26 weeks, and 52 weeks
Number of Participants With Treatment Emergent Anti-LY2189265 Antibodies
A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The total number of treatment emergent ADA was not analyzed at 26 weeks.
Time frame: Baseline through 52 weeks
Number of Self-reported Hypoglycemic Events at 26 and 52 Weeks
Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \[mg/dL\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks and 52 weeks
Rate of Self-reported Hypoglycemic Events at 52 Weeks
Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \[mg/dL\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Number of Participants With Adjudicated Pancreatitis at 52 Weeks Plus 30-day Follow up
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks plus 30-day follow up
Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks Plus 30-day Follow up
Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks plus 30-day follow up
Measurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC)
Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.
Time frame: 4 weeks, 13 weeks, 26 weeks, and 52 weeks
| Milestone | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| Started | 269 | 270 | 268 |
| Received at least 1 dose of study drug | 269 | 270 | 268 |
| Completed 26 weeks | 233 | 242 | 226 |
| Completed | 220 | 218 | 213 |
| Not completed | 49 | 52 | 55 |
| Withdrew: Adverse event | 14 | 8 | 12 |
| Withdrew: Withdrawal by subject | 11 | 19 | 14 |
| Withdrew: Sponsor decision | 5 | 4 | 7 |
| Withdrew: Physician decision | 1 | 1 | 2 |
| Withdrew: Entry criteria not met | 1 | 1 | 2 |
| Withdrew: Lack of efficacy | 2 | 3 | 4 |
| Withdrew: Protocol violation | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 15 | 13 | 9 |
| Withdrew: Treatment non-compliance | 0 | 2 | 3 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \[OAM\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.
| percentage of glycosylated hemoglobin | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) | -0.78 ± 0.06 | -0.71 ± 0.06 | -0.56 ± 0.06 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \[OAM\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.
| percentage of glycosylated hemoglobin | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c) | -0.70 ± 0.07 | -0.55 ± 0.07 | -0.51 ± 0.07 |
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, prior medication group, and treatment as factors included in the model.
| percentage of participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| HbA1c less than 7%, 26 weeks | 61.5 | 62.6 | 53.6 |
| HbA1c less than or equal to 6.5%, 26 weeks | 46.0 | 40.0 | 29.8 |
| HbA1c less than 7%, 52 weeks | 60.0 | 53.2 | 48.3 |
| HbA1c less than or equal to 6.5%, 52 weeks | 42.3 | 34.7 | 28.3 |
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.
| millimoles per liter (mmol/L) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=244, 247, 245) | -1.61 ± 0.13 | -1.46 ± 0.13 | -1.34 ± 0.13 |
| 52 weeks (n=207, 210, 194) | -1.56 ± 0.14 | -1.00 ± 0.14 | -1.15 ± 0.14 |
The SMBG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (daily mean) were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline daily mean as a covariate.
| millimoles per liter (mmol/L) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=195, 200, 211) | -1.98 ± 0.15 | -1.75 ± 0.14 | -1.68 ± 0.14 |
| 52 weeks (n=197, 200, 212) | -1.99 ± 0.16 | -1.71 ± 0.16 | -1.58 ± 0.15 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline body weight as a covariate.
| kilograms (kg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=267, 269, 267) | -2.29 ± 0.24 | -1.36 ± 0.24 | -2.22 ± 0.24 |
| 52 weeks (n=267, 269, 267) | -1.93 ± 0.29 | -1.09 ± 0.29 | -2.20 ± 0.29 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline BMI as a covariate.
| kilograms per meter squared (kg/m^2) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks | -0.86 ± 0.09 | -0.51 ± 0.09 | -0.82 ± 0.09 |
| 52 weeks | -0.73 ± 0.11 | -0.42 ± 0.10 | -0.83 ± 0.11 |
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline HOMA2 as a covariate, and participant as a random effect.
| percentage of HOMA2 | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| HOMA2-%B, 26 weeks (n=207, 207, 215) | 36.55 ± 3.42 | 28.96 ± 3.44 | 14.11 ± 3.37 |
| HOMA2-%B, 52 weeks (n=179, 185, 170) | 29.97 ± 3.46 | 22.5 ± 3.46 | 9.77 ± 3.51 |
| HOMA2-%S, 26 weeks (n=207, 207, 215) | 0.95 ± 2.29 | 2.71 ± 2.29 | 9.99 ± 2.25 |
| HOMA2-%S, 52 weeks (n=179, 185, 170) | 5.29 ± 2.43 | 1.84 ± 2.43 | 10.83 ± 2.48 |
The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=247, 251, 247) | 0.09 ± 0.33 | 0.19 ± 0.32 | 0.02 ± 0.32 |
| 52 weeks (n=247, 252, 248) | 0.39 ± 0.33 | -0.05 ± 0.33 | 0.28 ± 0.33 |
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=248, 254, 249) | 0.72 ± 0.19 | 0.63 ± 0.18 | 0.79 ± 0.18 |
| 52 weeks (n=249, 255, 250) | 0.45 ± 0.19 | 0.61 ± 0.19 | 0.75 ± 0.19 |
The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=244, 249, 241) | 1.93 ± 0.39 | 1.81 ± 0.38 | 2.04 ± 0.39 |
| 52 weeks (n=245, 251, 244) | 1.82 ± 0.44 | 1.29 ± 0.43 | 1.94 ± 0.44 |
The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) score is used to assess relative change in participant satisfaction from baseline. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 (much less satisfied) to +18 (much more satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Change Version | 12.92 ± 0.52 | 12.73 ± 0.50 | 12.58 ± 0.51 |
The Diabetes Symptoms Checklist-revised (DSC-r) was designed to assess the presence and perceived burden of diabetes-related symptoms. Respondents were to consider troublesomeness of 34 symptoms on a 5-point scale ranging from 5="extremely" to 1="not at all." For symptoms/side-effects not experienced, the item was scored as 0. Symptoms were grouped into the following subscales: psychology-fatigue, psychology-cognitive, neurology-pain, neurology-sensory, cardiology, ophthalmology, hypoglycemia, and hyperglycemia. Subscale scores were calculated as the sum of the given subscale divided by the total number of items in the scale. Total score was computed from the sum of the 8 subscales and ranged from 0 to 40. Higher scores indicate greater symptom burden. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=245, 253, 248) | 0.24 ± 0.36 | -0.16 ± 0.35 | 0.41 ± 0.35 |
| 52 weeks (n=247, 255, 249) | 0.49 ± 0.39 | 0.42 ± 0.39 | 0.59 ± 0.39 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks | 163 | 150 | 151 |
| 52 weeks | 179 | 177 | 170 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.
| milliseconds (msec) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| QTcF interval, 26 weeks (n=230, 237, 221) | 2.60 ± 1.17 | 1.38 ± 1.16 | -0.91 ± 1.18 |
| QTcF interval, 52 weeks (n=212, 212, 205) | 3.76 ± 1.20 | 0.73 ± 1.19 | -0.53 ± 1.21 |
| PR interval, 26 weeks (n=226, 235, 218) | -0.04 ± 1.12 | -0.01 ± 1.10 | -2.04 ± 1.13 |
| PR interval, 52 weeks (n=209, 210, 201) | 1.15 ± 1.18 | 1.53 ± 1.17 | -2.88 ± 1.19 |
Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects and baseline interval as a covariate.
| beats per minute (bpm) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=230, 237, 221) | 1.60 ± 0.60 | 2.57 ± 0.59 | 0.82 ± 0.61 |
| 52 weeks (n=212, 212, 205) | 2.02 ± 0.66 | 2.36 ± 0.66 | 1.27 ± 0.67 |
Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.
| beats per minute (bpm) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=244, 251, 239) | 2.39 ± 0.58 | 2.14 ± 0.57 | 1.59 ± 0.58 |
| 52 weeks (n=221, 219, 215) | 1.84 ± 0.57 | 1.63 ± 0.57 | 1.12 ± 0.57 |
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.
| milliliters of mercury (mmHg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| SBP, 26 weeks (n=244, 251, 239) | -1.89 ± 0.89 | -2.61 ± 0.88 | -0.91 ± 0.89 |
| SBP, 52 weeks (n=221, 219, 215) | -0.11 ± 0.88 | -2.74 ± 0.88 | -0.98 ± 0.88 |
| DBP, 26 weeks (n=244, 251, 239) | 0.05 ± 0.57 | -1.02 ± 0.56 | -0.64 ± 0.58 |
| DBP, 52 weeks (n=221, 219, 215) | 0.31 ± 0.60 | -1.37 ± 0.59 | -0.38 ± 0.60 |
Percent changes in total cholesterol were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.
| percentage change in total cholesterol | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=244, 244, 243) | -3.86 (-10.83 to 5.24) | -1.77 (-9.78 to 7.57) | -3.51 (-12.19 to 5.45) |
| 52 weeks (n=247, 248, 245) | -1.69 (-11.11 to 7.45) | -0.78 (-10.02 to 8.10) | -3.88 (-12.14 to 5.69) |
Percentage changes in HDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.
| percentage change in HDL-C | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=246, 244, 244) | 2.39 (-4.11 to 13.54) | 4.20 (-5.66 to 14.66) | 5.78 (-2.66 to 14.13) |
| 52 weeks (n=248, 248, 246) | 4.95 (-4.55 to 13.17) | 2.31 (-5.16 to 12.56) | 4.32 (-6.56 to 13.64) |
Percentage changes in LDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.
| percentage change in LDL-C | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=233, 231, 221) | -6.86 (-18.26 to 8.20) | -2.70 (-15.33 to 9.15) | -8.97 (-20.21 to 5.00) |
| 52 weeks (n=236, 240, 231) | -2.06 (-15.93 to 9.31) | -2.34 (-15.22 to 10.56) | -7.23 (-18.56 to 4.36) |
Percentage changes in triglycerides were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.
| percentage change in triglycerides | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks (n=252, 252, 253) | -2.35 (-22.32 to 13.61) | -1.96 (-21.66 to 22.63) | 2.56 (-16.00 to 23.79) |
| 52 weeks (n=255, 256, 254) | -4.27 (-22.91 to 19.23) | -0.86 (-22.31 to 25.37) | 1.91 (-21.65 to 24.04) |
Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured.
| units per liter (U/L) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| Amylase (total), 26 weeks | 7.00 (2.00 to 13.00) | 6.00 (0.00 to 13.00) | 4.00 (-2.00 to 10.00) |
| Amylase (total), 52 weeks | 5.50 (-1.00 to 13.00) | 5.00 (-1.00 to 13.00) | 4.00 (-2.00 to 9.00) |
| Amylase (PD), 26 weeks | 5.00 (2.00 to 9.00) | 4.00 (1.00 to 7.00) | 1.00 (-1.00 to 5.00) |
| Amylase (PD), 52 weeks | 4.00 (1.00 to 7.00) | 3.00 (0.00 to 8.00) | 2.00 (-1.00 to 5.00) |
| Lipase, 26 weeks | 7.00 (1.00 to 16.00) | 5.00 (0.00 to 13.00) | 1.00 (-4.00 to 8.00) |
| Lipase, 52 weeks | 5.00 (-1.00 to 13.00) | 5.00 (0.00 to 12.00) | 1.00 (-4.00 to 6.00) |
| picograms per milliliter (pcg/mL) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| 26 weeks | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| 52 weeks | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The total number of treatment emergent ADA was not analyzed at 26 weeks.
| participants | 1.5 mg or 0.75 mg LY2189265 |
|---|---|
| Number of Participants With Treatment Emergent Anti-LY2189265 Antibodies | 10 |
Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \[mg/dL\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| Severe, 26 weeks (n=241, 248, 236) | 0 | 0 | 0 |
| Severe, 52 weeks (n=214, 217, 199) | 0 | 0 | 0 |
| Documented Symptomatic, 26 weeks (n=241, 248, 236) | 2 | 6 | 2 |
| Documented Symptomatic, 52 weeks (n=214, 217, 199) | 7 | 8 | 2 |
| Asymptomatic, 26 weeks (n=241, 248, 236) | 19 | 9 | 13 |
| Asymptomatic, 52 weeks (n=214, 217, 199) | 5 | 9 | 9 |
Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \[mg/dL\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per year | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| Severe | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Documented Symptomatic | 0.62 ± 8.91 | 0.15 ± 0.72 | 0.09 ± 0.50 |
| Asymptomatic | 0.24 ± 1.26 | 0.30 ± 1.85 | 0.18 ± 0.79 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| Number of Participants With Adjudicated Pancreatitis at 52 Weeks Plus 30-day Follow up | 0 | 0 | 0 |
Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| Any CV Event | 1 | 2 | 1 |
| Any Fatal CV Event | 0 | 0 | 0 |
| Any Nonfatal CV Event | 1 | 2 | 1 |
Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.
| nanogram hours per milliliter (ng*hr/mL) | 1.5 mg LY2189265 | 0.75 mg LY2189265 |
|---|---|---|
| Measurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC) | 12036 ± 5385 | 5919 ± 1548 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.5 mg LY2189265 | — | 15/269 (5.6%) | 177/269 (65.8%) |
| 0.75 mg LY2189265 | — | 20/270 (7.4%) | 178/270 (65.9%) |
| Metformin | — | 16/268 (6%) | 170/268 (63.4%) |
| Event | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| Chest painGeneral disorders | 0/269 | 3/270 | 0/268 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/269 | 2/270 | 0/268 |
| SyncopeNervous system disorders | 0/269 | 2/270 | 0/268 |
| Ovarian fibromaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/155 | 0/152 | 1/147 |
| PregnancyPregnancy, puerperium and perinatal conditions | 1/155 | 0/152 | 0/147 |
| Angina pectorisCardiac disorders | 0/269 | 0/270 | 1/268 |
| Atrial fibrillationCardiac disorders | 0/269 | 0/270 | 1/268 |
| Cardiac failure congestiveCardiac disorders | 0/269 | 0/270 | 1/268 |
| Pericardial effusionCardiac disorders | 0/269 | 0/270 | 1/268 |
| Abdominal painGastrointestinal disorders | 0/269 | 0/270 | 1/268 |
| Event | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin |
|---|---|---|---|
| NauseaGastrointestinal disorders | 53/269 | 31/270 | 43/268 |
| DiarrhoeaGastrointestinal disorders | 31/269 | 26/270 | 39/268 |
| NasopharyngitisInfections and infestations | 14/269 | 9/270 | 28/268 |
| VomitingGastrointestinal disorders | 26/269 | 20/270 | 14/268 |
| HeadacheNervous system disorders | 10/269 | 14/270 | 20/268 |
| ConstipationGastrointestinal disorders | 18/269 | 12/270 | 3/268 |
| Decreased appetiteMetabolism and nutrition disorders | 18/269 | 12/270 | 12/268 |
| Upper respiratory tract infectionInfections and infestations | 16/269 | 17/270 | 8/268 |
| Abdominal distensionGastrointestinal disorders | 13/269 | 13/270 | 10/268 |
| Back painMusculoskeletal and connective tissue disorders | 5/269 | 9/270 | 12/268 |
Participants who received at least 1 dose of LY2189265 or Metformin.
| Age, Continuous(years) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin | Total |
|---|---|---|---|---|
| Mean | 55.51 ± 10.38 | 55.90 ± 10.68 | 55.26 ± 10.10 | 55.56 ± 10.38 |
| Sex: Female, Male(Participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin | Total |
|---|---|---|---|---|
| Female | 155 | 152 | 147 | 454 |
| Male | 114 | 118 | 121 | 353 |
| Ethnicity (NIH/OMB)(Participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin | Total |
|---|---|---|---|---|
| Hispanic or Latino | 90 | 87 | 95 | 272 |
| Not Hispanic or Latino | 179 | 183 | 173 | 535 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 29 | 28 | 28 | 85 |
| Asian | 21 | 20 | 20 | 61 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 17 | 22 | 14 | 53 |
| White | 201 | 198 | 201 | 600 |
| More than one race | 1 | 2 | 4 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin | Total |
|---|---|---|---|---|
| United States | 77 | 80 | 74 | 231 |
| Slovakia | 8 | 9 | 9 | 26 |
| Finland | 3 | 5 | 4 | 12 |
| Spain | 12 | 11 | 12 | 35 |
| United Kingdom | 0 | 1 | 1 | 2 |
| India | 9 | 11 | 9 | 29 |
| France | 12 | 12 | 13 | 37 |
| Czech Republic | 10 | 9 | 8 | 27 |
| Mexico | 24 | 25 | 23 | 72 |
| Canada | 10 | 9 | 11 | 30 |
| Puerto Rico | 14 | 10 | 15 | 39 |
| Argentina | 27 | 27 | 26 | 80 |
| Poland | 7 | 6 | 5 | 18 |
| Brazil | 2 | 2 | 3 | 7 |
| Croatia | 3 | 4 | 4 | 11 |
| Romania | 14 | 13 | 13 | 40 |
| South Africa | 12 | 11 | 12 | 35 |
| Germany | 22 | 21 | 21 | 64 |
| Korea, Republic of | 3 | 4 | 5 | 12 |
| Body Weight(kilograms (kg)) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin | Total |
|---|---|---|---|---|
| Mean | 92.67 ± 18.79 | 91.79 ± 18.67 | 92.40 ± 19.23 | 92.28 ± 18.87 |
| Body Mass Index (BMI)(kilograms per square meter (kg/m^2)) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin | Total |
|---|---|---|---|---|
| Mean | 33.66 ± 5.65 | 33.08 ± 5.84 | 33.05 ± 5.06 | 33.26 ± 5.53 |
| Duration of Diabetes(years) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Metformin | Total |
|---|---|---|---|---|
| Mean | 2.65 ± 1.50 | 2.60 ± 2.17 | 2.63 ± 1.77 | 2.63 ± 1.83 |
1 further baseline measures are reported on the registry.
The record gives a start of May 2010, a primary completion of Nov 2011 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 3 years 2 months after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide